

Asia-Pacific rises in biologics; India leads as top biotech investment hub amid global shifts.

India accelerates biotech leadership with clinical trials, global partnerships, and government support—offering prime opportunities for investors in biologics.

PUNE, MAHARASHTRA, INDIA, April 22, 2025 /EINPresswire.com/ -- As the world grapples with converging crises—climate change, economic uncertainty, regulatory upheaval, and capital scarcity—innovation is no longer a matter of progress but of survival. The global [biologics](#) market is witnessing substantial growth, driven by evolving industry trends and increasing demand for targeted therapies. With a market size of approximately \$468.74 billion in 2024, the sector is projected to expand significantly, reaching \$1,019.37 billion by 2032 at a CAGR of 15.3% from 2025 to 2032. This market forecast highlights the impact of rising chronic disease prevalence,

“

India’s biotech sector is transforming global healthcare with innovation, scale, and talent—making it the next big hub for biologics.”

Dr. Prashant S. Duraphe

advancements in biotechnology, and an expanding pipeline of innovative biologic products. The global business and scientific communities are facing a seismic shift, and nowhere is this more apparent than in the biopharmaceutical sector. While traditional biotech hubs in the West contend with policy volatility and funding constraints, countries in the Asia-Pacific region, led by India and China, are rapidly mobilizing to fill the innovation vacuum.

Biologics complex therapies derived from living organisms—are at the forefront of this transformation. Unlike conventional drugs, biologics offer more targeted, effective, and safer treatments for chronic and rare diseases. Global demand for these therapies continues to rise, and in response, the Asia-Pacific region has ignited a biologics boom, with India emerging as a global nexus for research, development, and manufacturing.

Download Free Sample Report: <https://epiicconsultancy.com/request-free-sample/?biologics-market>

India’s Moment of Momentum

India’s biologics and [biosimilars](#) sector has accelerated on multiple fronts. Over 95 biosimilars have received regulatory approvals in India—one of the highest globally. Late-stage clinical trials, especially in pediatric vaccines and monoclonal antibody therapies, dominate the landscape. These trials address both local and global healthcare priorities, such as immunization coverage, autoimmune diseases, and chronic respiratory conditions.

Key industry players have made bold moves. Indian firms are entering global markets through strategic settlements, regulatory approvals, and international partnerships. Several companies have received clearance to launch [next-generation therapies](#) in the U.S., further validating India's global credibility. Additionally, Indian firms are expanding their footprint abroad by acquiring advanced biologics facilities in the U.S., a clear signal of India's ambition to become a global manufacturing and innovation hub.

Crucially, the Indian government has stepped up with policy and infrastructure support. Initiatives like the National BioPharma Mission, supported by agencies such as the Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC), provide funding, incubation, and streamlined regulatory pathways. These mechanisms are aligned with global standards, including those of the U.S. FDA, enabling Indian-developed biologics to gain faster global market access.

Request For Customization @ <https://epiicconsultancy.com/request-free-sample/?biologics-market>

Regulatory and Scientific Shifts in the West

In contrast, Western biotech ecosystems—particularly in the U.S.—are experiencing strain. A recent vacated regulatory rule on diagnostic oversight highlights growing unpredictability in science policy. Simultaneously, key agencies are facing budgetary challenges, resulting in layoffs, reduced grant availability, and stalled programs. These headwinds have created barriers for early-stage startups and innovators, forcing many to look eastward for more stable and supportive ecosystems.

This disruption presents a unique window for international investors, venture funds, and strategic partners to diversify their biotech portfolios. Asia-Pacific offers not only lower cost structures but also rich talent pools, robust clinical trial capacity, and a surging demand for affordable biologics. India, with its demonstrated clinical and manufacturing prowess, is at the epicenter of this shift.

China's Expanding Pipeline

China, too, is making formidable strides. In just five years, the number of drug candidates in development has quintupled, with a strong emphasis on biologics. The country is investing heavily in next-generation technologies such as bispecific antibodies, cell therapies, and antibody-drug conjugates. With over 100 biosimilars in clinical development and more than 40 projected to enter the market in the coming years, China's ambition to become a biologics superpower is clear.

While China is leading in advanced biologics innovation, India stands out in affordability, clinical scale, and export readiness. Together, the two nations are reshaping the global biotech map and unlocking new opportunities for collaboration and investment.

Read More Insights: <https://epiicconsultancy.com/biologics-market/>

Asia-Pacific: The Future of Biologics

Asia-Pacific's transformation into a biologics epicenter reflects broader shifts in the global innovation landscape. Climate-induced disasters, geopolitical tensions, and public health crises are forcing governments and investors to rethink resilience. Biologics, with their potential to address urgent medical needs and reduce long-term healthcare costs, offer a compelling avenue for impact-driven growth.

In this context, software-driven platforms for clinical data analysis, AI-assisted drug discovery, and advanced manufacturing systems are complementing biologics development. As the intersection of biotech and technology deepens, India's established digital ecosystem further enhances its value proposition.

Segmentation by Product

- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Cell Therapy
- Gene Therapy
- Antisense, RNAi, & Molecular Therapy
- Others

Segmentation by Application

- Oncology
- Infectious Diseases
- Immunology
- Cardiovascular Disorders
- Hematological Disorders
- Rare Diseases
- Others

Segmentation by Source

- Microbial Sources
- Mammalian Sources
- Others

Segmentation by Route of Administration

- Injectable Biologics
- Subcutaneous
- Intravenous
- Oral Biologics
- Topical Biologics

Segmentation by End-user

- Hospitals
- Research Institutions
- Specialty Clinics

Conclusion

Investor Opportunity: Timing is Everything

The current moment presents a rare convergence of scientific opportunity and economic necessity. Global investors seeking stability, scalability, and innovation should look to India's thriving biologics sector. Early movers stand to benefit from not only strong returns but also meaningful contributions to global health equity.

India is not merely catching up—it is redefining the terms of biotech leadership. As biologics reshape the future of medicine, India is positioned to be both the engine of innovation and the supplier to the world.

Now is the time to invest.

Contact US:

sales@epiicconsultancy.com

info@epiicconsultancy.com

About us

Epiic Market Research & Consultancy is your trusted partner in driving business success. We specialize in delivering tailored market insights, strategic planning, and innovative solutions to empower startups, small businesses, and established enterprises. With expertise spanning life sciences, consumer goods, technology, and more, we provide actionable data that fosters informed decisions and sustainable growth.

Manoj Khavate

Epiic Market Research & Consultancy

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/805204625>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.